This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / BioSyent Closes Oral Science Acquisition
Business acquisition closing

BioSyent Closes Oral Science Acquisition

Analysis based on 9 articles · First reported Feb 09, 2026 · Last updated Mar 02, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The successful closing of BioSyent's acquisition of BioSyent===Oral Science is expected to positively impact BioSyent's stock price due to expanded market presence and potential for increased revenue. This transaction also signals continued consolidation and growth within the healthcare and pharmaceutical sectors.

Pharmaceuticals Dental Care Healthcare
Event Summary

BioSyent Inc. has successfully closed its previously announced acquisition of BioSyent===Oral Science, a privately-owned Canadian distributor of specialized healthcare products. The aggregate purchase price was $25.5 million, satisfied by a cash payment of $22.5 million and the issue of 234,192 BioSyent common shares. Additionally, $0.2 million of the cash payment will be satisfied with the grant of 12,666 Restricted Share Units to certain Oral Science employees. BioSyent funded the cash component with $16.3 million of its liquid cash on hand and a $6.0 million term loan and $2.0 million draw on a revolving credit line facility from Royal Bank of Canada. The transaction is subject to final approval by the TSX Venture Exchange. BioSyent's Board of Directors also approved a separate grant of 8,682 RSUs to other employees.

Key Actions
100 BioSyent closed acquisition BioSyent===Oral Science
80 BioSyent issued common shares BioSyent===Oral Science
60 BioSyent granted Restricted Share Units BioSyent===Oral Science
50 Royal Bank of Canada provided term loan and credit facility BioSyent
Entities Involved
stock
BioSyent
BioSyent successfully closed the acquisition of BioSyent===Oral Science for $25.5 million, expanding its oral health business unit. This acquisition is expected to contribute to BioSyent's growth and profitability.
Importance 100 Sentiment 70
subs
BioSyent===Oral Science
BioSyent===Oral Science has been acquired by BioSyent, providing its shareholders with a significant cash payment and BioSyent common shares. The company will continue its operations as part of BioSyent's oral health business unit.
Importance 90 Sentiment 70
stock
Royal Bank of Canada
Royal Bank of Canada provided BioSyent with a $6.0 million 1-Year Senior Secured Demand Term Loan and a $2.0 million draw on a Senior Secured Demand Revolving Credit Line Facility to fund the acquisition.
Importance 30 Sentiment 10
exch
TSX Venture Exchange
The TSX Venture Exchange is mentioned as the listing exchange for BioSyent and is responsible for the final approval of the acquisition, which qualifies as an 'Expedited Acquisition' under its policy.
Importance 20 Sentiment 10
per
René C. Goehrum
René C. Goehrum is the President and CEO of BioSyent Inc. and is listed as the contact for further information regarding the acquisition.
Importance 10 Sentiment 20
Relationships
BioSyent related ↔ BioSyent===Oral Science
René C. Goehrum related ↔ BioSyent
Royal Bank of Canada related ↔ BioSyent
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.